好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Prevalence of Delirium in Brain Tumor Patients: A Systematic Review and Meta-analysis
Neuro-oncology
P3 - Poster Session 3 (11:45 AM-12:45 PM)
6-014
To determine the prevalence rates of delirium in hospitalized patients with brain tumors.
Delirium in hospitalized patients is associated with poor outcomes such as increased morbidity, mortality, and length of hospital stay. Although delirium is frequently reported as a complication of patients with brain tumors, its general prevalence is unknown. 

Following PRISMA guidelines, we conducted a systematic review and meta-analysis searching PubMed, Scopus, and Web of Science for prevalence or incidence of delirium in primary and secondary brain tumors. Studies from January 2009 to June 2024 were included. Only high-quality studies were included. We used random-effects models for summary estimates. We performed subgroup analyses by type of tumor, location of tumor, and delirium sub-type. We also analyzed the association of delirium with length of stay. This review was pre-registered on PROSPERO (CRS42024565359).

Of 452 studies screened, 22 were included, representing 35,484 patients. The overall prevalence of delirium in patients with brain tumors was 16% (95% CI 10-24%). The prevalence of delirium in patients with low-grade gliomas, high-grade gliomas, and brain metastases were 10%, 24%, and 43% respectively. Compared to the occipital lobe, the highest relative risk for delirium occurred for tumors in the limbic system (RR 5.01; 95% CI 1.88-16.35), then frontal (RR 3.01, CI 1.33, 7.89), and temporal (RR 2.94, CI 1.27-7.83) lobes. were more likely to have hypoactive (RR 5.20, 95% CI 3.74-7.44) or hyperactive delirium (RR 3.24, 95% CI 2.29-4.67) rather than mixed. Delirium was associated with an increased length of stay (4.62 days longer; 95% CI 3.23-6.01). There was large heterogeneity across studies.

We confirmed the high prevalence of delirium in patients hospitalized with brain tumors. Notably, delirium rates seemed to reflect brain tumor location, grade, and origin, suggesting the potential importance of specific pathophysiologies. 
Authors/Disclosures
Zachary Tentor
PRESENTER 		Mr. Tentor has nothing to disclose.
Alexander Finnemore, Medical Student Mr. Finnemore has nothing to disclose.
Paul Miller, Research Assistant Mr. Miller has received personal compensation for serving as an employee of Hillsdale College.
Joshua Davis Mr. Davis has nothing to disclose.
Erika L. Juarez Martinez, MD, PhD Dr. Juarez Martinez has nothing to disclose.
Eyal Y. Kimchi, MD, PhD (Northwestern University) The institution of Dr. Kimchi has received research support from NIH. The institution of an immediate family member of Dr. Kimchi has received research support from NIH.
Charlotta Lindvall, MD, PhD The institution of Dr. Lindvall has received research support from National Institutes of Health.
John Y. Rhee, MD, MPH (Dana Farber Cancer Institute, Harvard Medical School) Dr. Rhee has stock in NTAP. Dr. Rhee has stock in TSLA. Dr. Rhee has stock in BABA. Dr. Rhee has stock in ZM. Dr. Rhee has stock in GM. Dr. Rhee has stock in PFF. Dr. Rhee has stock in AMZN. Dr. Rhee has stock in META. Dr. Rhee has stock in GE. The institution of Dr. Rhee has received research support from 好色先生. Dr. Rhee has received personal compensation in the range of $0-$499 for serving as a Director of the Hippocratic Forum with Hippocratic Society.